$3.99
+0.14
(+3.64%)▲
Insights on Caribou Biosciences
Revenue is down for the last 2 quarters, 23.66M → 3.55M (in $), with an average decrease of 85.0% per quarter
Netprofit is down for the last 2 quarters, -10.00M → -34.50M (in $), with an average decrease of 245.0% per quarter
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 55.8%
4.76%
Downside
Day's Volatility :6.63%
Upside
1.97%
13.78%
Downside
52 Weeks Volatility :59.95%
Upside
53.55%
Period | Caribou Biosciences | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -24.72% | -0.4% | 0.0% |
6 Months | 4.72% | 9.6% | 0.0% |
1 Year | -10.14% | 3.9% | -1.3% |
3 Years | -75.55% | 12.8% | -22.1% |
Market Capitalization | 347.7M |
Book Value | $4.17 |
Earnings Per Share (EPS) | -1.38 |
Wall Street Target Price | 20.0 |
Profit Margin | -296.05% |
Operating Margin TTM | -1052.33% |
Return On Assets TTM | -18.0% |
Return On Equity TTM | -30.5% |
Revenue TTM | 34.5M |
Revenue Per Share TTM | 0.47 |
Quarterly Revenue Growth YOY | -3.5999999999999996% |
Gross Profit TTM | -68.4M |
EBITDA | -112.5M |
Diluted Eps TTM | -1.38 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.79 |
EPS Estimate Next Year | -2.08 |
EPS Estimate Current Quarter | -0.37 |
EPS Estimate Next Quarter | -0.41 |
What analysts predicted
Upside of 401.25%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 5.8M | - |
Net Income | -23.4M | - |
Net Profit Margin | -404.82% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 12.4M | ↑ 113.56% |
Net Income | -34.3M | ↑ 46.42% |
Net Profit Margin | -277.55% | ↑ 127.27% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 9.6M | ↓ 22.35% |
Net Income | -66.9M | ↑ 95.07% |
Net Profit Margin | -697.26% | ↓ 419.71% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 13.9M | ↑ 44.31% |
Net Income | -99.4M | ↑ 48.56% |
Net Profit Margin | -717.79% | ↓ 20.53% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 34.5M | ↑ 148.91% |
Net Income | -102.1M | ↑ 2.66% |
Net Profit Margin | -296.05% | ↑ 421.74% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.3M | ↓ 21.21% |
Net Income | -26.8M | ↑ 7.19% |
Net Profit Margin | -810.08% | ↓ 214.59% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.7M | ↑ 11.78% |
Net Income | -27.0M | ↑ 0.87% |
Net Profit Margin | -731.01% | ↑ 79.07% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.5M | ↓ 5.15% |
Net Income | -25.0M | ↓ 7.42% |
Net Profit Margin | -713.51% | ↑ 17.5% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.8M | ↑ 7.22% |
Net Income | -29.5M | ↑ 18.14% |
Net Profit Margin | -786.13% | ↓ 72.62% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 23.7M | ↑ 530.15% |
Net Income | -10.0M | ↓ 66.12% |
Net Profit Margin | -42.27% | ↑ 743.86% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.6M | ↓ 84.96% |
Net Income | -34.5M | ↑ 244.98% |
Net Profit Margin | -969.79% | ↓ 927.52% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 61.9M | - |
Total Liabilities | 54.5M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 36.0M | ↓ 41.8% |
Total Liabilities | 59.5M | ↑ 9.2% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 442.4M | ↑ 1127.2% |
Total Liabilities | 54.5M | ↓ 8.33% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 373.8M | ↓ 15.51% |
Total Liabilities | 72.9M | ↑ 33.67% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 441.0M | ↑ 17.98% |
Total Liabilities | 72.6M | ↓ 0.45% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 398.8M | ↓ 5.35% |
Total Liabilities | 74.7M | ↑ 1.68% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 373.8M | ↓ 6.28% |
Total Liabilities | 72.9M | ↓ 2.43% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 347.5M | ↓ 7.04% |
Total Liabilities | 69.2M | ↓ 5.08% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 349.6M | ↑ 0.63% |
Total Liabilities | 80.2M | ↑ 15.9% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 457.5M | ↑ 30.85% |
Total Liabilities | 59.3M | ↓ 26.11% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 441.0M | ↓ 3.62% |
Total Liabilities | 72.6M | ↑ 22.47% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -32.0M | - |
Investing Cash Flow | 27.2M | - |
Financing Cash Flow | 172.0K | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.2M | ↑ 3.78% |
Investing Cash Flow | 6.4M | ↓ 76.63% |
Financing Cash Flow | 1.7M | ↑ 908.72% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -32.5M | ↓ 2.1% |
Investing Cash Flow | -176.4M | ↓ 2872.23% |
Financing Cash Flow | 433.4M | ↑ 24881.5% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -91.0M | ↑ 179.73% |
Investing Cash Flow | -93.2M | ↓ 47.14% |
Financing Cash Flow | 2.1M | ↓ 99.51% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.4M | ↑ 2.3% |
Investing Cash Flow | -8.3M | ↓ 40.32% |
Financing Cash Flow | 654.0K | ↑ 80.66% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -25.0M | ↑ 11.92% |
Investing Cash Flow | 1.2M | ↓ 114.03% |
Financing Cash Flow | 127.0K | ↓ 80.58% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -27.9M | ↑ 11.56% |
Investing Cash Flow | 20.7M | ↑ 1669.49% |
Financing Cash Flow | 1.6M | ↑ 1192.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -15.2M | ↓ 45.65% |
Investing Cash Flow | 11.1M | ↓ 46.56% |
Financing Cash Flow | 17.6M | ↑ 970.1% |
Sell
Neutral
Buy
Caribou Biosciences is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Caribou Biosciences | -24.57% | 4.72% | -10.14% | -75.55% | -75.55% |
Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Caribou Biosciences | NA | NA | NA | -1.79 | -0.3 | -0.18 | NA | 4.17 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Caribou Biosciences | Buy | $347.7M | -75.55% | NA | -296.05% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
BlackRock Inc
Partner Fund Management LP
Avidity Partners Management LP
State Street Corporation
Vanguard Group Inc
Deerfield Management Co
Caribou Biosciences’s price-to-earnings ratio stands at None
Read Morecaribou biosciences is a leading biotechnology company in genome engineering. we develop technology-based solutions for cellular engineering and analysis based on the crispr-cas9 technology platform. cas9, when paired with a guide rna, cuts double-stranded dna allowing for specific changes to dna. these site-specific dna modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. forbes magazine has called cas9 the protein that "could change biotech forever" and the new york times has noted that "the pace of new discoveries and applications is dizzying." caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. interested in joining our team? please contact us at jobs at cariboub
Organization | Caribou Biosciences |
Employees | 158 |
CEO | Dr. Rachel E. Haurwitz Ph.D. |
Industry | Services |